Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study.


Goy A., Sinha R., Williams M. E., Besisik S., Drach J., Ramchandren R., ...More

Journal of clinical oncology : official journal of the American Society of Clinical Oncology, vol.31, no.29, pp.3688-95, 2013 (SCI-Expanded) identifier identifier identifier

Abstract

Purpose